New for 2026

What Are Wegovy Pills? The New Daily Tablet, Explained for the UK (2026)

On 11 June 2026, the MHRA approved Wegovy tablets. Making the UK the first country in Europe with an oral GLP-1 licensed for weight management. No pen, no fridge, no needle. But there are strict fasting rules, and fakes will follow. Here is the complete picture.

Medically reviewed by the GLP1Guide Editorial Team Updated 9 min read 5 cited sources

What the Wegovy pill actually is

The Wegovy pill is a once-daily tablet containing 25 mg of semaglutide at its target dose. The same active ingredient as the Wegovy injection. It is made by Novo Nordisk and was approved by the MHRA on 11 June 2026 for adults living with obesity (BMI ≥30), or overweight (BMI 27 to 30) with at least one weight-related condition, alongside a reduced-calorie diet and increased physical activity.

Getting a peptide like semaglutide through the stomach is genuinely hard. Stomach acid destroys it. The tablet uses an absorption enhancer (called SNAC) that protects the drug and helps it pass through the stomach lining. That technology is also why the dosing rules are unusually strict, and why the daily dose (25 mg) is so much larger than the weekly injection dose (2.4 mg): only a small fraction of each tablet is actually absorbed.

Not the same as Rybelsus

Rybelsus is an older oral semaglutide tablet licensed only for type 2 diabetes, at much lower doses (up to 14 mg). The Wegovy pill is a different product at a higher dose, licensed specifically for weight management. They are not interchangeable.

What OASIS 4 found

Approval was based on the OASIS 4 phase 3 trial, published in the New England Journal of Medicine. 307 adults with obesity or overweight (without diabetes), treated for 64 weeks alongside lifestyle changes:

13.6%average weight loss at 25 mg (vs 2.4% on placebo), counting everyone regardless of adherence
16.6%average weight loss when everyone stayed on treatment (vs 2.7% placebo)
74%reported gastrointestinal side effects (mostly mild-to-moderate and temporary), vs 42% on placebo
6.9%stopped treatment due to side effects. Similar to the injection trials

In plain terms: the pill works somewhat less powerfully than the 2.4 mg injection (14.9% in STEP 1) on average, but far better than placebo, and for the significant minority of people who cannot face needles, "slightly less powerful but actually taken" beats "more powerful but avoided".

How to take it: the fasting rules

This is the part that makes or breaks the tablet. Absorption collapses if you take it wrong, so the rules are strict:

  • Take one tablet, once a day, first thing in the morning.
  • Swallow it whole on an empty stomach. After at least 8 hours without food or drink (overnight fasting covers this).
  • Take it with a small sip of plain water only (up to about 120 ml / half a glass). No squash, no coffee, no tea.
  • Then wait at least 30 minutes before eating, drinking anything else, or taking other oral medicines.

If 30 minutes of waiting each morning genuinely does not fit your life, say so at your consultation. The weekly injection may suit you better. There is no prize for struggling with the wrong format.

The dosing schedule

Like the injection, the tablet escalates gradually so your gut can adjust. The MHRA advises starting at the lowest dose and stepping up no faster than monthly:

StageDaily doseMinimum time
Start1.5 mg1 month
Step 24 mg1 month
Step 39 mg1 month
Maintenance25 mgOngoing

Already on the 2.4 mg injection? The MHRA has said patients treated privately with the 2.4 mg weekly injection can be transitioned straight onto the 25 mg daily tablet, but that switch should always be organised by your prescriber, never self-managed.

UK availability, NHS status and price

As of July 2026, the picture is:

  • Private prescriptions: available within weeks of approval through GPhC-registered online pharmacies and clinics. Expected pricing is around £200-£260 per month. Broadly in line with, or slightly below, the injection.
  • NHS: not yet. NHS funding requires a NICE appraisal, which has not been completed for the tablet. Expect a long wait.
  • No fridge, no sharps bin: tablets store at room temperature. A genuine quality-of-life upgrade for travel and discretion.
Expect fakes. Check before you buy

New, high-demand medicines attract counterfeiters immediately, and "weight-loss pills" are the most counterfeited category in the UK. Only use GPhC-registered pharmacies that verify your ID and medical history. Run the checks in our fake medicines guide, and read our Wegovy pill ID checks page before ordering. oGovy.co.uk manually verifies which pharmacies are genuinely licensed to supply the tablet. A sensible first stop.

Frequently asked questions

Are Wegovy pills available in the UK yet? +

Yes. The MHRA approved Wegovy tablets on 11 June 2026, and Novo Nordisk expected private prescriptions to be available within weeks. NHS availability requires a separate NICE appraisal, which has not been completed.

How much weight do you lose on the Wegovy pill? +

In the OASIS 4 trial, adults lost an average of 13.6% of body weight over 64 weeks (16.6% with full adherence) versus 2.4% on placebo, alongside diet and activity changes.

Why do you have to fast around the tablet? +

Food, drink and even other medicines dramatically reduce how much semaglutide your body absorbs from the tablet. Taking it on an empty stomach with a small sip of water and waiting 30 minutes is what makes the dose work as intended.

Is the Wegovy pill the same as Rybelsus? +

No. Both are oral semaglutide, but Rybelsus is licensed only for type 2 diabetes at lower doses (up to 14 mg). The Wegovy pill targets 25 mg daily and is licensed for weight management. They are different products and not interchangeable.

Pill or injection, which is better? +

The injection produces somewhat greater average weight loss (14.9% in STEP 1 at 2.4 mg; 20.7% at 7.2 mg in STEP UP) and needs no fasting routine. The pill avoids needles, fridges and sharps bins. The best option is the one you will actually take consistently (a conversation for your prescriber.

References & official sources

Show all 5 cited sources, with study authors +
  1. MHRA / Novo Nordisk. Wegovy pill (semaglutide tablets) UK approval announcement, 11 June 2026: www.biospace.com/press-releases/novo-nordisk-wegovy-pill-semaglutide-tablets-becomes-first-daily-glp-1-weight-loss-pill-approved-in-the-uk
  2. Wharton S et al. Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity (OASIS 4). NEJM 2025: www.nejm.org/doi/full/10.1056/NEJMoa2500969
  3. The Pharmaceutical Journal. MHRA approves semaglutide oral tablets for weight loss (June 2026): pharmaceutical-journal.com/article/news/mhra-approves-semaglutide-oral-tablets-for-weight-loss
  4. MHRA. Yellow Card reporting scheme: yellowcard.mhra.gov.uk/
  5. GPhC. Check a pharmacy registration: www.pharmacyregulation.org/registers
Remember: this page is general education for UK readers, not personal medical advice. Mounjaro, Wegovy and Ozempic are prescription-only medicines. Your prescriber and pharmacist know your history, so their guidance always comes first. Spot a side effect? Report it via the MHRA Yellow Card scheme.